The SEC fined former CEO Ankit Mahadevia $112,500 and former CFO Satyavrat Shukla $75,000 in a settled January 2026 order. Spero's letter of Jan 20, 2026 says the SEC does not intend to recommend action against it.
Latest Spero Therapeutics news
We have not published a story on Spero Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $50.8 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Spero Therapeutics
Has Spero Therapeutics settled a lawsuit?
Our latest story on this, dated Aug 12, 2026: "Spero says SEC closed its investigation without action against it; two ex-executives settled". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Spero Therapeutics?
Spero Therapeutics, Inc. trades under the ticker SPRO on NASDAQ.
Where is Spero Therapeutics listed?
Spero Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:SPRO; BMV:SPRO; GETTEX:2HA; LS:A2H63F.
What is the SEC CIK of Spero Therapeutics?
The SEC Central Index Key (CIK) for Spero Therapeutics, Inc. is 1701108. Its filings are on SEC EDGAR.
How many shares does Spero Therapeutics have outstanding?
58,234,827 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is Spero Therapeutics listed under?
Our directory records Spero Therapeutics, Inc. under United States.
What does Spero Therapeutics do?
Our directory classifies Spero Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Spero Therapeutics?
The ISIN recorded for Spero Therapeutics, Inc. is US84833T1034.
Does aibio.space cover Spero Therapeutics?
aibio.space lists Spero Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Spero Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was Spero Therapeutics's revenue last year?
$66.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Spero Therapeutics profitable?
Spero Therapeutics, Inc. reported net income of $8.6 million for the fiscal year ended Dec 31, 2025, and used $12.6 million of cash in operations, per its annual report to the SEC.
How much does Spero Therapeutics spend on research and development?
$38.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Spero Therapeutics have?
$50.8 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Spero Therapeutics (SPRO) stock news?
Our latest story on Spero Therapeutics, dated Aug 12, 2026: "Spero says SEC closed its investigation without action against it; two ex-executives settled". The SEC fined former CEO Ankit Mahadevia $112,500 and former CFO Satyavrat Shukla $75,000 in a settled January 2026 order. Spero's letter of Jan 20, 2026 says the SEC does not intend to recommend action against it. Source.
Investor discussion: Spero Therapeutics
Members talk about Spero Therapeutics (SPRO). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Spero Therapeutics, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 2.02,5.02,7.01,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:SPRO on TradingView.
SEC filings and registration
SEC name
Spero Therapeutics, Inc.
CIK
1701108
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
SPRO (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02139
Phone
857-242-1600
Shares outstanding
58,234,827 as of 2026-08-07 (10-Q filed 2026-08-12)
Former names
Spero Therapeutics, LLC
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Spero Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SPRO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio